See more : Trio Resources, Inc. (TRII) Income Statement Analysis – Financial Results
Complete financial analysis of ACADIA Pharmaceuticals Inc. (ACAD) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of ACADIA Pharmaceuticals Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Qing Song Health Co.,Ltd. (6931.TWO) Income Statement Analysis – Financial Results
- Mack-Cali Realty Corporation (CLI) Income Statement Analysis – Financial Results
- Fram Skandinavien AB (FRAM-B.ST) Income Statement Analysis – Financial Results
- Shenzhen Neptunus Interlong Bio-technique Company Limited (8329.HK) Income Statement Analysis – Financial Results
- Chiyoda Corporation (CHYCY) Income Statement Analysis – Financial Results
ACADIA Pharmaceuticals Inc. (ACAD)
About ACADIA Pharmaceuticals Inc.
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's pipeline include, pimavanserin, under phase 3 development for the treatment of Alzheimer's disease psychosis, and negative symptoms of schizophrenia; Trofinetide, a novel synthetic analog, under phase 3 development for the treatment of Rett syndrome; ACP-044, a novel first-in-class orally administered non-opioid analgesic, under phase 2 development for treating acute and chronic pain; and ACP-319, a positive allosteric modulator of the muscarinic receptor, under phase 1 development for treating schizophrenia and cognition in Alzheimer's. ACADIA Pharmaceuticals Inc. was founded in 1993 and is headquartered in San Diego, California.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | 2007 | 2006 | 2005 | 2004 | 2003 | 2002 | 2001 | 2000 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 726.44M | 517.24M | 484.15M | 441.76M | 339.08M | 223.81M | 124.90M | 17.33M | 61.00K | 120.00K | 1.15M | 4.91M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Cost of Revenue | 45.73M | 10.17M | 19.14M | 20.55M | 19.60M | 18.33M | 13.06M | 4.41M | 76.37M | 60.60M | 26.72M | 18.79M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 680.71M | 507.07M | 465.00M | 421.21M | 319.48M | 205.48M | 111.84M | 12.93M | -76.31M | -60.48M | -25.58M | -13.89M | 2.07M | 42.14M | 6.40M | 1.59M | 7.56M | 8.13M | 10.96M | 4.60M | 7.38M | 6.28M | 3.71M | 4.31M |
| Gross Profit Ratio | 93.70% | 98.03% | 96.05% | 95.35% | 94.22% | 91.81% | 89.54% | 74.58% | -125,095.08% | -50,401.67% | -2,233.80% | -283.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% |
| Research & Development | 351.62M | 361.58M | 239.42M | 319.13M | 240.39M | 187.16M | 149.19M | 99.28M | 73.87M | 60.60M | 26.72M | 18.79M | 17.31M | 20.58M | 41.59M | 56.75M | 57.94M | 49.40M | 30.85M | 23.45M | 16.94M | 14.92M | 13.09M | 9.73M |
| General & Administrative | 393.07M | 363.59M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Selling & Marketing | 9.40M | 5.50M | 41.80M | 51.10M | 38.30M | 39.80M | 15.60M | 1.60M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 402.47M | 369.09M | 396.03M | 388.66M | 325.64M | 265.76M | 255.06M | 186.46M | 90.80M | 32.75M | 12.72M | 7.00M | 7.61M | 6.46M | 10.28M | 11.82M | 12.27M | 11.35M | 15.91M | 7.25M | 4.18M | 3.98M | 3.76M | 3.00M |
| Other Expenses | 0.00 | 3.54M | 2.33M | -997.00K | 997.00K | -1.84M | 3.98M | 1.33M | 2.50M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -3.56M | 7.53M | 2.36M | 0.00 | 0.00 | 2.15M | 2.85M |
| Operating Expenses | 754.09M | 730.67M | 635.44M | 707.79M | 566.02M | 452.92M | 404.25M | 285.74M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Cost & Expenses | 799.82M | 740.83M | 654.58M | 728.34M | 585.62M | 471.25M | 417.31M | 290.15M | 164.67M | 93.35M | 39.44M | 25.79M | 24.92M | 27.04M | 51.87M | 68.57M | 70.21M | 57.19M | 46.76M | 30.70M | 21.12M | 18.90M | 18.99M | 15.58M |
| Interest Income | 17.23M | 6.61M | 591.00K | 6.61M | 11.17M | 5.35M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 82.00K | 409.00K | 2.92M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 6.61M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 37.00K | 86.00K | 181.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 5.55M | 2.03M | 3.34M | 2.93M | 2.77M | 3.01M | 2.71M | 1.83M | 647.00K | 206.00K | 79.00K | 109.00K | 285.00K | 607.00K | 1.11M | 1.04M | 768.00K | -146.00K | 1.03M | 1.31M | 1.34M | 1.40M | 0.00 | 0.00 |
| EBITDA | -67.83M | -221.57M | -167.10M | -286.59M | -243.78M | -244.44M | -289.70M | -270.99M | -163.47M | -93.02M | -38.22M | -20.78M | -22.48M | 15.70M | -44.36M | -66.98M | -62.65M | -49.05M | -32.93M | -24.18M | -12.40M | -11.22M | -15.28M | -11.27M |
| EBITDA Ratio | -9.34% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,337.82% | -425.64% | -1,091.78% | 37.26% | -693.19% | -4,212.45% | -819.14% | -646.92% | -317.45% | -538.40% | -168.01% | -178.84% | -411.39% | -261.34% |
| Operating Income | -73.38M | -223.60M | -170.44M | -286.59M | -246.55M | -247.44M | -292.41M | -272.82M | -164.61M | -93.23M | -38.30M | -20.89M | -22.85M | 15.09M | -45.47M | -66.98M | -62.65M | -49.05M | -35.81M | -26.10M | -13.74M | -12.63M | -15.28M | -11.27M |
| Operating Income Ratio | -10.10% | -43.23% | -35.20% | -64.87% | -72.71% | -110.56% | -234.11% | -1,574.14% | -269,855.74% | -77,691.67% | -3,344.72% | -425.64% | -1,105.56% | 35.82% | -710.55% | -4,212.45% | -829.31% | -603.15% | -326.81% | -566.76% | -186.22% | -201.19% | -411.39% | -261.34% |
| Total Other Income/Expenses | 22.34M | 10.15M | 2.92M | 5.61M | 12.16M | 3.51M | 4.13M | 2.76M | 499.00K | 755.00K | 349.00K | 37.00K | 87.00K | 45.00K | 323.00K | 2.73M | 6.26M | 3.96M | -4.55M | 178.20K | 0.00 | 0.00 | 15.28M | 11.27M |
| Income Before Tax | -51.04M | -213.44M | -167.52M | -280.97M | -234.38M | -243.94M | -288.28M | -270.05M | -164.11M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | -7.03% | -41.27% | -34.60% | -63.60% | -69.12% | -108.99% | -230.81% | -1,558.20% | -269,037.70% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 10.25M | 2.53M | 351.00K | 611.00K | 876.00K | 1.26M | 1.12M | 1.34M | 330.00K | -206.00K | 0.00 | -109.00K | 0.00 | 0.00 | 0.00 | -1.04M | 0.00 | -3.86M | -200.00 | -200.00 | 352.60K | 242.30K | 14.41M | 10.19M |
| Net Income | -61.29M | -215.98M | -167.87M | -281.58M | -235.26M | -245.19M | -289.40M | -271.39M | -164.44M | -92.48M | -37.95M | -20.85M | -22.77M | 15.14M | -45.15M | -64.24M | -56.39M | -45.05M | -34.14M | -25.92M | -14.09M | -12.87M | -14.41M | -10.19M |
| Net Income Ratio | -8.44% | -41.76% | -34.67% | -63.74% | -69.38% | -109.56% | -231.71% | -1,565.94% | -269,578.69% | -77,062.50% | -3,314.24% | -424.88% | -1,101.35% | 35.93% | -705.50% | -4,040.50% | -746.39% | -553.89% | -311.56% | -562.89% | -191.00% | -205.05% | -387.88% | -236.41% |
| EPS | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -9.66 | -8.86 | -11.93 | -9.53 |
| EPS Diluted | -0.37 | -1.34 | -1.05 | -1.79 | -1.60 | -1.94 | -2.36 | -2.34 | -1.63 | -0.95 | -0.44 | -0.38 | -0.44 | 0.39 | -1.20 | -1.73 | -1.60 | -1.61 | -1.55 | -2.50 | -1.24 | -8.86 | -11.93 | -9.53 |
| Weighted Avg Shares Out | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 54.87M | 52.18M | 38.59M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 1.46M | 1.45M | 1.21M | 1.07M |
| Weighted Avg Shares Out (Dil) | 163.82M | 161.68M | 160.49M | 157.33M | 147.20M | 126.58M | 122.60M | 115.86M | 100.63M | 97.25M | 85.72M | 55.12M | 52.18M | 38.72M | 37.48M | 37.11M | 35.21M | 27.92M | 22.01M | 10.35M | 11.37M | 1.45M | 1.21M | 1.07M |
Acadia Pharmaceuticals Stock Sinks After Schizophrenia Drug Study Falls Short
Shares of Acadia Pharmaceuticals (ACAD) plunged more than 16% Tuesday after one of its current drugs failed to meet its goal for expanded use in a Phase 3 trial.
Acadia (ACAD) Down as Schizophrenia Study on Nuplazid Fails
Acadia (ACAD) tumbles after its late-stage study on pimavanserin to treat negative symptoms of schizophrenia fails to achieve the primary goal with statistical significance.
Why Are Airline Stocks Down Today?
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE:DAL) with its latest quarterly outlook.
Why Are Airline Stocks Down Today?
Airline stocks are down today as investors deal with several bits of bad news for the industry on Tuesday! Starting off the negative news today is Delta Air Lines (NYSE: DAL ) with its latest quarterly outlook.
Why Is Acadia Pharmaceuticals (ACAD) Stock Down 18% Today?
Acadia Pharmaceuticals (NASDAQ: ACAD ) stock is falling on Tuesday after the company released results from a Phase 3 clinical trial of pimavanserin. Pimavanserin is a drug in development at Acadia Pharmaceuticals as a treatment for negative symptoms of schizophrenia.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK, March 11, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Acadia Pharma's stock falls 15% after failed drug trial
Shares of Acadia Pharmaceuticals Inc. dropped more than 15% in the extended session Monday after one of the pharma company's drugs failed to meet goals of a late-stage trial about a schizophrenia treatment.
Acadia Pharmaceuticals' schizophrenia drug fails in late-stage study
Acadia Pharmaceuticals said on Monday its antipsychotic drug failed to significantly improve negative symptoms of schizophrenia, including poor socialization and lack of motivation, in a late-stage study.
Acadia Pharmaceuticals Announces Top-Line Results from Phase 3 ADVANCE-2 Trial of Pimavanserin in Negative Symptoms of Schizophrenia
SAN DIEGO--(BUSINESS WIRE)--Acadia Pharmaceuticals Inc. (Nasdaq: ACAD) today announced top-line results from the Phase 3 ADVANCE-2 trial evaluating pimavanserin for the treatment of negative symptoms of schizophrenia. Pimavanserin did not demonstrate a statistically significant improvement over placebo on the study's...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of ACADIA Pharmaceuticals Inc. - ACAD
NEW YORK , March 3, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of ACADIA Pharmaceuticals Inc. ("ACADIA" or the "Company") (NASDAQ: ACAD). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
Source: https://incomestatements.info
Category: Stock Reports